MOTS-c Peptide: Research, Benefits & How It Works

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded directly by mitochondrial DNA that has been researched for its role in metabolic regulation, insulin sensitivity, exercise-related signaling, and age-associated physical decline.

Discovered in 2015 by researchers at the University of Southern California, MOTS-c belongs to a small family of mitochondrial-derived peptides — a class of signaling molecules that challenged the long-held view of mitochondria as purely energy-producing organelles. Rather than only receiving instructions from the nucleus, mitochondria appear to send hormonal-style signals back to the rest of the cell and body, with MOTS-c among the most studied of these messengers.

What Is MOTS-c?

MOTS-c is a chain of 16 amino acids (MRWQEMGYIFYPRKLR, molecular weight ~2.2 kDa) encoded within a short open reading frame in the mitochondrial 12S rRNA region — not in nuclear DNA.

This origin is unusual. Nearly all signaling peptides studied in biology are encoded by the nuclear genome. MOTS-c, like the earlier-discovered mitochondrial peptide humanin, is translated from the mitochondrial genome itself, which is inherited maternally and contains only 37 genes by the classical count. The discovery of MOTS-c demonstrated that hidden within that small genome are additional short sequences encoding bioactive peptides.

Unlike synthetic research peptides such as BPC-157, MOTS-c is endogenously produced — the body makes it, primarily in skeletal muscle, and its production increases in response to exercise and metabolic stress. The MOTS-c used in research settings is produced synthetically, but the molecule itself is a natural signaling peptide.

Research has investigated MOTS-c for its relationship with AMPK signaling, insulin sensitivity, glucose metabolism, adipose tissue function, exercise capacity, age-related metabolic decline, and cellular stress responses.

How Does MOTS-c Work?

MOTS-c has been studied for its interaction with several metabolic and cellular pathways. Researchers have investigated its relationship with:

• AMPK activation — MOTS-c’s best-characterized mechanism. The original 2015 study reported that MOTS-c inhibits the folate cycle and its tethered de novo purine biosynthesis, causing accumulation of the intermediate AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), itself a known AMPK activator. AMPK is a central cellular energy sensor regulating glucose uptake and fatty acid oxidation
• The folate–methionine cycle — by acting on folate-dependent one-carbon metabolism, MOTS-c creates a metabolic cascade linking one-carbon metabolism to energy sensing
• Nuclear translocation under stress — a 2018 study reported that under metabolic stress, MOTS-c moves from mitochondria into the cell nucleus, where it interacts with nuclear DNA to regulate genes tied to the antioxidant response element (ARE) — a direct mitochondria-to-nucleus communication channel
• Skeletal muscle signaling — the original discovery paper identified skeletal muscle as MOTS-c’s primary target organ, with treated muscle showing increased glucose uptake
• Exercise-induced production — a 2021 study reported that vigorous exercise increased MOTS-c levels approximately 12-fold in human skeletal muscle and about 50% in circulation, positioning MOTS-c as one of the signals the body generates during physical activity

Key Takeaway: MOTS-c is particularly interesting to researchers because it represents a new category of biology — a mitochondrial genome-encoded signal that regulates whole-body metabolism through AMPK and direct nuclear communication — though nearly all of this work remains preclinical.

Potential Benefits of MOTS-c

Metabolic & Insulin Sensitivity Research

Metabolic regulation is the most extensively studied area of MOTS-c research.

In the landmark 2015 study, researchers reported that MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity. Treated animals showed improved glucose clearance and increased skeletal muscle glucose uptake through AMPK-dependent mechanisms. The researchers concluded that mitochondria may actively regulate metabolic homeostasis at the cellular and organismal level via peptides encoded within their genome.

A separate 2019 study reported that circulating MOTS-c levels decline with age in both mice and humans, and that administering MOTS-c to aged mice improved insulin sensitivity and metabolic function — suggesting that the age-related decline of this endogenous signal may contribute to age-associated metabolic dysfunction.

Exercise & Physical Performance Research

In 2021, researchers published a study in Nature Communications investigating MOTS-c as an exercise-induced regulator of physical decline.

The study reported two key findings. First, in human volunteers, vigorous cycling exercise increased MOTS-c levels roughly 12-fold in skeletal muscle and about 50% in blood plasma during and immediately after exercise. Second, when mice were treated with MOTS-c, physical performance improved at every age tested — young (2 months), middle-aged (12 months), and old (22 months). A two-week treatment approximately doubled running capacity in aged mice, and even mice that began treatment very late in life showed improved grip strength, stride length, and walking speed. In high-fat-diet-fed mice, MOTS-c treatment also improved performance while treated animals gained less weight than untreated controls.

The researchers described MOTS-c as an exercise-induced mitochondrial-encoded regulator — sometimes summarized as an “exercise mimetic” signal, meaning it activates some of the same metabolic pathways triggered by physical activity.

Adipose & Thermogenesis Research

Adipose tissue biology represents another studied branch of MOTS-c research.

A 2019 study reported that MOTS-c increased adipose thermogenic activation to promote cold adaptation in mice — in other words, treated animals showed greater activation of heat-producing capacity in fat tissue under cold stress conditions.

Related 2019 research investigated MOTS-c in a model of ovariectomy-induced metabolic dysfunction (a mouse model of menopause-associated metabolic change), reporting that MOTS-c treatment alleviated ovariectomy-induced obesity and liver lipid deposition while regulating adipose homeostasis.

Liver & NASH-Related Research

Liver metabolism has emerged as an active area of MOTS-c investigation.

A 2023 study in Cell Reports reported that MOTS-c interacts with Bcl-2 to alleviate nonalcoholic steatohepatitis (NASH) progression in a mouse model — identifying a direct mitochondrial protein target for MOTS-c’s protective effects under NASH-induced metabolic stress.

Separately, the MOTS-c analog CB4211 — developed by CohBar as an improved analog of the MOTS-c peptide — became the first mitochondria-based therapeutic to enter clinical testing. In a Phase 1a/1b trial completed in 2021, the Phase 1b portion enrolled 20 obese subjects with nonalcoholic fatty liver disease who received the analog daily for four weeks. The company reported the analog was well tolerated with reductions in liver injury biomarkers (ALT −21%, AST −28%) and glucose (−6%) versus placebo. These were exploratory endpoints in a small early-phase trial of the analog, not of MOTS-c itself.

Immune & Autoimmune Diabetes Research

A 2021 study in Cell Reports investigated MOTS-c in a mouse model of autoimmune (type 1) diabetes.

Researchers reported that daily MOTS-c administration in NOD mice prevented pancreatic islet destruction, lowered glycolytic rates in CD4+ T cells, and was associated with higher insulin concentrations during glucose tolerance testing. Serum MOTS-c levels were also found to be negatively correlated with CD4+ T cell glycolytic rate in samples from human type 1 diabetes patients — an observational association, not an intervention result.

It is important to distinguish these animal and observational findings from demonstrated clinical outcomes in humans.

Nuclear Signaling Research

A 2018 study in Cell Metabolism added a striking mechanistic finding: under metabolic stress, MOTS-c translocates from mitochondria to the nucleus, where it regulates nuclear gene expression tied to the antioxidant response element.

This established MOTS-c as a participant in retrograde signaling — communication flowing from mitochondria back to the nuclear genome — and suggested that part of its metabolic role involves directly reprogramming stress-response gene expression.

MOTS-c vs. Other Peptides

MOTS-c has a different research profile from peptides such as BPC-157, TB-500, and GHK-Cu, which are researched for different biological pathways.

BPC-157 is a synthetic 15-amino-acid peptide studied primarily in animal models for tendon, ligament, muscle, and gastrointestinal healing — a tissue-repair profile, not a metabolic one.

TB-500 (a fragment of thymosin beta-4) has been studied in animal models for cell migration and tissue repair, with a research focus overlapping BPC-157’s in musculoskeletal healing.

GHK-Cu is a naturally occurring copper-binding peptide studied mainly for skin biology, collagen-related processes, and tissue remodeling.

Humanin is MOTS-c’s closest relative — the first mitochondrial-derived peptide, discovered in 2001. Humanin is a 24-amino-acid peptide studied primarily for cytoprotective and anti-apoptotic signaling, whereas MOTS-c’s research centers on metabolic regulation through AMPK.

MOTS-c’s research is more closely associated with:

Mitochondrial Signaling → AMPK Activation → Metabolic Homeostasis → Exercise & Aging Biology

This makes MOTS-c particularly relevant to research involving metabolic regulation, exercise physiology, and age-associated metabolic decline — a distinct lane from the tissue-repair peptides.

Regulatory Status

MOTS-c’s regulatory position is worth stating plainly:

• MOTS-c is not FDA approved for any indication, and no MOTS-c drug product has been approved anywhere as a medicine.
• MOTS-c itself has not undergone human clinical trials. The only human trial data in this area comes from CB4211, a synthetic analog of MOTS-c developed by CohBar, which completed a Phase 1a/1b study in 2021 — an analog is a different molecule, and its results do not establish anything about MOTS-c itself.
• MOTS-c is not named on the World Anti-Doping Agency’s prohibited list, but athletes should check current anti-doping rules, as peptide categories are broad and updated regularly.

Regulatory developments do not change the underlying evidence base: human efficacy data for MOTS-c does not exist.

What Does the Research Say?

The MOTS-c literature is substantial for a molecule discovered in 2015 — and it provides a basis for continued research into mitochondrial regulation of metabolism, particularly in insulin sensitivity, exercise-related signaling, adipose biology, and age-associated physical decline.

However, the evidence gaps are significant and should be understood clearly:

First, essentially all interventional studies were conducted in mice or cell models. The human data consists of observational findings: exercise increases MOTS-c in human muscle and plasma, and circulating MOTS-c declines with age in humans. No study has tested MOTS-c administration in humans.

Second, the one human trial in this space tested CB4211, an analog — and it was a small Phase 1a/1b safety and exploratory-biomarker study (65 healthy adults in Phase 1a, 20 obese NAFLD subjects in Phase 1b), not an efficacy trial of MOTS-c.

Third, a 2021 genetic study identified a mitochondrial DNA polymorphism (m.1382A>C) in the MOTS-c-encoding region associated with longevity in Japanese centenarians — the variant produces a functionally distinct MOTS-c (K14Q substitution) — but genetic associations do not establish therapeutic effects.

Promising animal research on a mitochondrial signaling peptide is not the same as proven outcomes in people, and enthusiasm around MOTS-c runs well ahead of what the human evidence supports.

Frequently Asked Questions

What is MOTS-c?

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded by mitochondrial DNA, discovered in 2015 by researchers at the University of Southern California. It has been researched primarily in animal models for metabolic regulation, insulin sensitivity, and exercise-related signaling.

What does the research show?

Animal studies have reported improved insulin sensitivity, protection against diet-induced obesity, enhanced exercise capacity (including roughly doubled running capacity in aged mice), increased adipose thermogenic activation, and prevention of pancreatic islet destruction in a mouse model of autoimmune diabetes. Human data is observational: exercise increases MOTS-c levels, and circulating levels decline with age.

Is MOTS-c FDA approved?

No. MOTS-c is not FDA approved for any indication and has not undergone human clinical trials. Only a synthetic analog (CB4211) has entered Phase 1 testing, and an analog is a different molecule.

Is MOTS-c naturally occurring?

Yes. Unlike purely synthetic research peptides, MOTS-c is endogenously produced — the body makes it, primarily in skeletal muscle, with production increasing during exercise and metabolic stress. The MOTS-c used in research is produced synthetically, but the molecule itself is a natural signaling peptide.

How is MOTS-c different from humanin?

Humanin (discovered 2001) and MOTS-c (discovered 2015) are both mitochondrial-derived peptides, but they differ in size and research focus. Humanin is a 24-amino-acid peptide studied mainly for cytoprotective and anti-apoptotic signaling; MOTS-c is a 16-amino-acid peptide studied mainly for metabolic regulation through AMPK activation.

Has MOTS-c been tested in humans?

Not as an intervention. No human trial of MOTS-c itself has been conducted. Human research is limited to observational findings — exercise-induced increases in muscle and plasma MOTS-c, age-related declines in circulating levels, and a genetic variant associated with longevity. The CB4211 analog’s Phase 1a/1b trial tested a different molecule.

The Bottom Line

MOTS-c is one of the most intriguing metabolic research peptides discovered in the last decade, with a growing body of animal studies investigating its role in insulin sensitivity, exercise-related signaling, adipose biology, and age-associated physical decline — all through a novel mechanism: a mitochondrial genome-encoded signal acting on AMPK and the cell nucleus.

The animal research is genuinely compelling — particularly the exercise-capacity findings in aged mice and the metabolic protection in diet-induced obesity models. But it is still animal research, and no human intervention data for MOTS-c exists.

For researchers interested in mitochondrial biology, metabolic regulation, and the emerging science of mitochondria-to-nucleus signaling, MOTS-c remains an important and actively discussed area of ongoing preclinical research.

Explore MOTS-c

Learn more about MOTS-c and explore our research-focused MOTS-c peptide at Vonox Labs.

Research. Test. Learn.

Ver materiales de investigación: Tienda VONOX Labs

Research Use Only: Vonox Labs products are intended strictly for laboratory and research purposes and are not intended for human or veterinary consumption. This information is provided for educational purposes only and is not medical advice.

Scientific References

• Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–454. (Discovery paper: 16-aa peptide encoded in mitochondrial 12S rRNA; skeletal muscle target; folate cycle inhibition → AICAR accumulation → AMPK activation; prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity in mice.)
• Kim KH, et al. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 2018;28:516–524.e7. (MOTS-c moves from mitochondria to the nucleus under metabolic stress to regulate antioxidant response element-linked gene expression.)
• Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12:470. (Exercise increased MOTS-c ~12-fold in human muscle and ~50% in plasma; treatment improved running capacity, grip strength, and gait in young, middle-aged, and aged mice; high-fat-diet mice gained less weight.)
• Kim SJ, et al. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiol Rep. 2019;7(13):e14171. (Circulating MOTS-c declines with age in mice and humans; administration improved insulin sensitivity in aged mice.)
• Lu H, et al. Mitochondrial-derived peptide MOTS-c increases adipose thermogenic activation to promote cold adaptation. Int J Mol Sci. 2019;20:2456. (Increased adipose thermogenic capacity under cold stress in mice.)
• Lu H, et al. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction. J Mol Med. 2019;97:473–485. (Alleviated ovariectomy-induced obesity and liver lipid deposition in mice.)
• Zempo H, et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging. 2021;13(2):1692–1717. (m.1382A>C mtDNA variant producing a K14Q-substituted MOTS-c associated with exceptional longevity in Japanese centenarians.)
• Mitochondrial-encoded MOTS-c prevents pancreatic islet destruction in autoimmune diabetes. Cell Rep. 2021. (Daily MOTS-c prevented islet destruction and lowered CD4+ T cell glycolysis in NOD mice; serum MOTS-c negatively correlated with T cell glycolysis in human type 1 diabetes samples.)
• The mitochondrial genome-encoded peptide MOTS-c interacts with Bcl-2 to alleviate nonalcoholic steatohepatitis progression. Cell Rep. 2023. (MOTS-c–Bcl-2 interaction identified as a mitochondrial target in a mouse NASH model.)
• CohBar, Inc. Positive topline results from the Phase 1a/1b study of CB4211 under development for NASH and obesity. 2021. (CB4211, a synthetic MOTS-c analog — not MOTS-c itself — completed Phase 1a in 65 healthy adults and Phase 1b in 20 obese subjects with NAFLD; reported tolerability and exploratory reductions in ALT, AST, and glucose versus placebo.)